|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q114561142
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010758.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q114561142
|
|
035
|
|
|
‡a
(OCoLC)Q114561142
|
|
100
|
0 |
|
‡a
Diana Hernández-Romero
‡c
researcher
‡9
en
|
|
670
|
|
|
‡a
Author's An insight of novel pharmacological therapies in hypertrophic cardiomyopathy.
|
|
670
|
|
|
‡a
Author's Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis
|
|
670
|
|
|
‡a
Author's Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test
|
|
670
|
|
|
‡a
Author's CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis.
|
|
670
|
|
|
‡a
Author's CALU polymorphism A29809G affects calumenin availability involving vascular calcification
|
|
670
|
|
|
‡a
Author's Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy.
|
|
670
|
|
|
‡a
Author's Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy
|
|
670
|
|
|
‡a
Author's Comparative determination and monitoring of biomarkers of necrosis and myocardial remodeling between radiofrequency ablation and cryoablation
|
|
670
|
|
|
‡a
Author's Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?
|
|
670
|
|
|
‡a
Author's Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State
|
|
670
|
|
|
‡a
Author's Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease
|
|
670
|
|
|
‡a
Author's Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation.
|
|
670
|
|
|
‡a
Author's Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk
|
|
670
|
|
|
‡a
Author's Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy
|
|
670
|
|
|
‡a
Author's High-sensitivity troponin T and copeptin in non-ST acute coronary syndromes: implications for prognosis and role of hsTnT and copeptin in non-STEACS.
|
|
670
|
|
|
‡a
Author's High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery.
|
|
670
|
|
|
‡a
Author's Identification and confirmation of haptoglobin as a potential serum biomarker in hypertrophic cardiomyopathy using proteomic approaches
|
|
670
|
|
|
‡a
Author's Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy
|
|
670
|
|
|
‡a
Author's Implications of pharmacogenetics for oral anticoagulants metabolism.
|
|
670
|
|
|
‡a
Author's Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: a pilot study
|
|
670
|
|
|
‡a
Author's Inhibition of enzymes involved in collagen cross-linking reduces vascular smooth muscle cell calcification
|
|
670
|
|
|
‡a
Author's Interleukin-6 and high-sensitivity C-reactive protein for the prediction of outcomes in non-ST-segment elevation acute coronary syndromes
|
|
670
|
|
|
‡a
Author's Lone atrial fibrillation - a diagnosis of exclusion
|
|
670
|
|
|
‡a
Author's Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion.
|
|
670
|
|
|
‡a
Author's New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
|
|
670
|
|
|
‡a
Author's Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy
|
|
670
|
|
|
‡a
Author's Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.
|
|
670
|
|
|
‡a
Author's Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold.
|
|
670
|
|
|
‡a
Author's Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
|
|
670
|
|
|
‡a
Author's Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy
|
|
670
|
|
|
‡a
Author's Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes.
|
|
670
|
|
|
‡a
Author's Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin
|
|
670
|
|
|
‡a
Author's Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction
|
|
670
|
|
|
‡a
Author's The prognostic role of the adiponectin levels in atrial fibrillation
|
|
670
|
|
|
‡a
Author's The prognostic value of biomarkers after a premature myocardial infarction
|
|
670
|
|
|
‡a
Author's TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy
|
|
670
|
|
|
‡a
Author's Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery
|
|
919
|
|
|
‡a
highsensitivitytroponintandcopeptininnonstacutecoronarysyndromesimplicationsforprognosisandroleofhstntandcopeptininnonsteacs
‡A
High-sensitivity troponin T and copeptin in non-ST acute coronary syndromes: implications for prognosis and role of hsTnT and copeptin in non-STEACS.
‡9
1
|
|
919
|
|
|
‡a
identificationandconfirmationofhaptoglobinasapotentialserumbiomarkerinhypertrophiccardiomyopathyusingproteomicapproaches
‡A
Identification and confirmation of haptoglobin as a potential serum biomarker in hypertrophic cardiomyopathy using proteomic approaches
‡9
1
|
|
919
|
|
|
‡a
impactofpolymorphismsinthereninangiotensinaldosteronesystemonhypertrophiccardiomyopathy
‡A
Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy
‡9
1
|
|
919
|
|
|
‡a
implicationsofpharmacogeneticsfororalanticoagulantsmetabolism
‡A
Implications of pharmacogenetics for oral anticoagulants metabolism.
‡9
1
|
|
919
|
|
|
‡a
influenceofcardiacresynchronizationtherapyonindicesofinflammationtheprothromboticstateandtissueremodelinginsystolicheartfailureapilotstudy
‡A
Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: a pilot study
‡9
1
|
|
919
|
|
|
‡a
inhibitionofenzymesinvolvedincollagencrosslinkingreducesvascularsmoothmusclecellcalcification
‡A
Inhibition of enzymes involved in collagen cross-linking reduces vascular smooth muscle cell calcification
‡9
1
|
|
919
|
|
|
‡a
interleukin6andhighsensitivity100reactiveproteinforthepredictionofoutcomesinnonstsegmentelevationacutecoronarysyndromes
‡A
Interleukin-6 and high-sensitivity C-reactive protein for the prediction of outcomes in non-ST-segment elevation acute coronary syndromes
‡9
1
|
|
919
|
|
|
‡a
loneatrialfibrillationadiagnosisofexclusion
‡A
Lone atrial fibrillation - a diagnosis of exclusion
‡9
1
|
|
919
|
|
|
‡a
longtermpredictorsofthromboemboliceventsinnonvalvularatrialfibrillationpatientsundergoingelectricalcardioversion
‡A
Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion.
‡9
1
|
|
919
|
|
|
‡a
newapproachestotheroleofthrombininacutecoronarysyndromesquovadisbivalirudinadirectthrombininhibitor
‡A
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
‡9
1
|
|
919
|
|
|
‡a
plasmalevelsofvonwillebrandfactorareincreasedinpatientswithhypertrophiccardiomyopathy
‡A
Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy
‡9
1
|
|
919
|
|
|
‡a
plasmavonwillebrandfactorlevelsareanindependentriskfactorforadverseeventsincludingmortalityandmajorbleedinginanticoagulatedatrialfibrillationpatients
‡A
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.
‡9
1
|
|
919
|
|
|
‡a
plateletreactivityovertimeincoronaryarterydiseasepatientstreatedwithabioabsorbableeverolimuselutingscaffold
‡A
Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold.
‡9
1
|
|
919
|
|
|
‡a
predictivevalueofthecha2ds2vascscoreinatrialfibrillationpatientsathighriskforstrokedespiteoralanticoagulation
‡A
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
‡9
1
|
|
919
|
|
|
‡a
serumlevelsofhighsensitivitytroponintanovelmarkerforcardiacremodelinginhypertrophiccardiomyopathy
‡A
Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy
‡9
1
|
|
919
|
|
|
‡a
smallsizecirculatingmicroparticlesinacutecoronarysyndromesrelevancetofibrinolyticstatusreparativemarkersandoutcomes
‡A
Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes.
‡9
1
|
|
919
|
|
|
‡a
smallsizeplateletmicroparticlestriggerplateletandmonocytefunctionalityandmodulatethrombogenesisviapselectin
‡A
Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin
‡9
1
|
|
919
|
|
|
‡a
synergismbetweenfactor124ctandfactor13val34leupolymorphismsinfibrinolytictherapyinacutemyocardialinfarction
‡A
Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction
‡9
1
|
|
919
|
|
|
‡a
prognosticroleoftheadiponectinlevelsinatrialfibrillation
‡A
The prognostic role of the adiponectin levels in atrial fibrillation
‡9
1
|
|
919
|
|
|
‡a
prognosticvalueofbiomarkersafteraprematuremyocardialinfarction
‡A
The prognostic value of biomarkers after a premature myocardial infarction
‡9
1
|
|
919
|
|
|
‡a
tweakandntprobnplevelspredictexercisecapacityinhypertrophiccardiomyopathy
‡A
TWEAK and NT-proBNP levels predict exercise capacity in hypertrophic cardiomyopathy
‡9
1
|
|
919
|
|
|
‡a
vonwillebrandfactorisassociatedwithatrialfibrillationdevelopmentinischaemicpatientsaftercardiacsurgery
‡A
Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery
‡9
1
|
|
919
|
|
|
‡a
highsensitivitytroponintasabiomarkerforthedevelopmentofatrialfibrillationaftercardiacsurgery
‡A
High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery.
‡9
1
|
|
919
|
|
|
‡a
geneticpolymorphismsandatrialfibrillationinsightsintotheprothromboticstateandthromboembolicrisk
‡A
Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk
‡9
1
|
|
919
|
|
|
‡a
galectin3asamarkerofinterstitialatrialremodellinginvolvedinatrialfibrillation
‡A
Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation.
‡9
1
|
|
919
|
|
|
‡a
galectin3andβtraceproteinconcentrationsarehigherinclinicallyunaffectedpatientswithfabrydisease
‡A
Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease
‡9
1
|
|
919
|
|
|
‡a
effectsofbodymassindexonthelipidprofileandbiomarkersofinflammationandafibrinolyticandprothromboticstate
‡A
Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State
‡9
1
|
|
919
|
|
|
‡a
doesvonwillebrandfactorimprovethepredictiveabilityofcurrentriskstratificationscoresinpatientswithatrialfibrillation
‡A
Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?
‡9
1
|
|
919
|
|
|
‡a
comparativedeterminationandmonitoringofbiomarkersofnecrosisandmyocardialremodelingbetweenradiofrequencyablationandcryoablation
‡A
Comparative determination and monitoring of biomarkers of necrosis and myocardial remodeling between radiofrequency ablation and cryoablation
‡9
1
|
|
919
|
|
|
‡a
collagenpeptidesinterstitialremodellingandsuddencardiacdeathinhypertrophiccardiomyopathy
‡A
Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy
‡9
1
|
|
919
|
|
|
‡a
clinicalimplicationsofnonsarcomericgenepolymorphismsinhypertrophiccardiomyopathy
‡A
Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy.
‡9
1
|
|
919
|
|
|
‡a
calupolymorphisma29809gaffectscalumeninavailabilityinvolvingvascularcalcification
‡A
CALU polymorphism A29809G affects calumenin availability involving vascular calcification
‡9
1
|
|
919
|
|
|
‡a
calua29809gpolymorphismincoronaryatherothrombosisimplicationsforcoronarycalcificationandprognosis
‡A
CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis.
‡9
1
|
|
919
|
|
|
‡a
bleedingriskpredictioninpatientswithdualantiplatelettherapyundergoingcoronaryarterybypassgraftingsurgeryusingarapidpointofcareplateletfunctiontest
‡A
Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test
‡9
1
|
|
919
|
|
|
‡a
biomarkersofpathophysiologyinhypertrophiccardiomyopathyimplicationsforclinicalmanagementandprognosis
‡A
Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis
‡9
1
|
|
919
|
|
|
‡a
insightofnovelpharmacologicaltherapiesinhypertrophiccardiomyopathy
‡A
An insight of novel pharmacological therapies in hypertrophic cardiomyopathy.
‡9
1
|
|
919
|
|
|
‡a
growthdifferentiationfactor15anovelbiomarkerrelatedwithdiseaseseverityinpatientswithhypertrophiccardiomyopathy
‡A
Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy
‡9
1
|
|
996
|
|
|
‡2
DNB|133755568
|
|
996
|
|
|
‡2
LC|no2024079533
|
|
996
|
|
|
‡2
ISNI|0000000505901075
|
|
996
|
|
|
‡2
LC|no2008012747
|
|
996
|
|
|
‡2
J9U|987007345149805171
|
|
996
|
|
|
‡2
DNB|1251758169
|
|
996
|
|
|
‡2
PLWABN|9813255264205606
|
|
996
|
|
|
‡2
BNE|XX1393457
|
|
996
|
|
|
‡2
BNF|18102525
|
|
996
|
|
|
‡2
KRNLK|KAC200004896
|
|
996
|
|
|
‡2
NKC|jo20231185274
|
|
996
|
|
|
‡2
CAOONL|ncf11556533
|
|
996
|
|
|
‡2
ICCU|CFIV254038
|
|
996
|
|
|
‡2
LC|n 93011716
|
|
996
|
|
|
‡2
LC|ns2020000437
|
|
996
|
|
|
‡2
BNE|XX5226670
|
|
996
|
|
|
‡2
BNC|981058514390906706
|
|
996
|
|
|
‡2
NTA|435022830
|
|
996
|
|
|
‡2
ISNI|0000000107183813
|
|
996
|
|
|
‡2
LC|n 2021060409
|
|
996
|
|
|
‡2
SUDOC|232714711
|
|
996
|
|
|
‡2
N6I|vtls002703446
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
